Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Complex ANDAs To Be Allowed Pre-Submission Product Meetings

Executive Summary

FDA will be able to give scientific advice and sponsors can familiarize reviewers with upcoming generic applications for complex products under new provision in GDUFA II.

Advertisement

Related Content

US FDA Commits To Meeting With Complex ANDA Sponsors, Works Hard To Avoid It
FDA Web Portal Eases Pre-ANDA Meeting Request Process
Complex ANDAs: Early Meetings With FDA Can Generate Bonus Communication
Generic Drug User Fees Will Jump More Than 50% In FY 2018
ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
EpiPen Familiarity May Prove Tough Hurdle For Generics
ANDA Approval Speed-Up Leaves Sponsors With Less Margin For Error
Biosimilars Reviews Could Be Extended Two Months In BsUFA II
Pre-ANDA Meeting Goals May Be Created In GDUFA II
Biosimilar User Fee Meeting Schedule Allows FDA Data “Pre-Review”

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119384

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel